1. Analysis of omarigliptin forced degradation products by ultra-fast liquid chromatography, mass spectrometry, and in vitro toxicity assay.
- Author
-
Mohr A, de Souza Barbosa F, Wingert NR, Takeuchi CK, Garcia L, Ribeiro MFN, Arbo MD, de Oliveira TF, and Steppe M
- Subjects
- Chromatography, High Pressure Liquid methods, Mass Spectrometry methods, Humans, Cell Survival drug effects, Reproducibility of Results, Hypoglycemic Agents chemistry, Hypoglycemic Agents analysis, Oxidation-Reduction, Linear Models, Drug Stability, Pyrans chemistry, Pyrans analysis, Pyrans toxicity, Heterocyclic Compounds, 2-Ring chemistry, Heterocyclic Compounds, 2-Ring analysis, Heterocyclic Compounds, 2-Ring toxicity
- Abstract
Omarigliptin (OMG) is an antidiabetic drug indicated for the treatment of type 2 diabetes mellitus. Forced degradation studies are practical experiments to evaluate the stability of drugs and to establish degradation profiles. Herein, we present the investigation of the degradation products (DPs) of OMG formed under various stress conditions. OMG was subjected to hydrolytic (alkaline and acidic), oxidative, thermal, and photolytic forced degradation. A stability-indicating ultra-fast liquid chromatography method was applied to separate and quantify OMG and its DPs. Five DPs were adequately separated and detected in less than 6 min, while other published methods detected four DPs. MS was applied to identify and obtain information on the structural elucidation of the DPs. Three m/z DPs confirmed previously published research, and two novel DPs were described in this paper. The toxicity of OMG and its DPs were investigated for the first time using in vitro cytotoxicity assays, and the sample under oxidative conditions presented significant cytotoxicity. Based on the results from forced degradation studies, OMG was found to be labile to hydrolysis, oxidation, photolytic, and thermal stress conditions. The results of this study contribute to the quality control and stability profile of OMG., (© 2024 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF